Chimeric epitope based vaccines for tick borne infections
用于蜱传感染的嵌合表位疫苗
基本信息
- 批准号:9982205
- 负责人:
- 金额:$ 64.37万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-07-24 至 2023-06-30
- 项目状态:已结题
- 来源:
- 关键词:AddressAnaplasma phagocytophilumAnaplasmosisAreaAsiaAttenuatedBlack-legged TickBloodBorrelia afzeliiBorrelia burgdorferiBorrelia gariniiCanadaCanis familiarisCenters for Disease Control and Prevention (U.S.)ClinicalCommunicable DiseasesDevelopmentDiagnosisDiseaseEpitopesEuropeGoalsHL-60 CellsHumanImmune responseImmunityImmunizationImmunoglobulin GIncidenceIndividualInfectionIxodesKnowledgeLyme DiseaseLyme Disease VaccinesMammalsMeasurementModelingMouse StrainsMusNatureOmpA proteinOrder SpirochaetalesOspA proteinOspC proteinPopulationPreventionPrevention strategyProductionProteinsPublic HealthRecombinantsReportingSamplingSeverity of illnessSubunit VaccinesSurfaceTick-Borne DiseasesTick-Borne InfectionsTicksTimeUnited States National Institutes of HealthVaccinatedVaccinationVaccine AntigenVaccinesVariantVirulence FactorsWorkbactericidebasecitrate carrierco-infectioncompanion animalcost efficientdesigngranulocytehuman diseaseimmunogenicityinnovationpathogenpreventprotective efficacyseroconversionsurveillance studytick-borne pathogentransmission processuptakevaccine development
项目摘要
Lyme disease (LD) and human granulocytic anaplasmosis (HGA), are significant public health threats. LD is caused by
Borreliella burgdorferi, B. garinii, B. bavariensis, and B. afzelii and HGA by Anaplasma phagocytophilum (Ap). The CDC
estimates there are ~330,000 clinician diagnosed LD cases per year in the US with high numbers in Europe and Canada.
Since HGA was designated as a reportable disease in 2009, case numbers have steadily increased. In 2017, 4,151 cases
of HGA were reported in the US (a number considered to be a significant underestimate). Current preventive strategies
for tick-borne diseases are inadequate and ineffective. With the expansion of the endemic regions for LD and HGA,
better recognition of their true incidence, the severity of these diseases, and the potential complications associated
with co-infection, a vaccine that protects against multiple tick borne pathogens is needed. In this study we will develop
chimeric, linear epitope-based vaccine antigens (chimeritope) for LD and HGA. Proof of principle for chimeritope
vaccines has been demonstrated by the successful development of a highly efficacious canine LD vaccine. The basic
strategy that was applied in developing the canine vaccine will be employed to construct a human vaccine for both LD
and HGA. The chimeric vaccinogens will consist of defined linear epitopes of the OspA, B and C proteins of the LD
spirochetes and defined domains of Ap proteins OmpA, Asp14, and AipA. The polyvalent nature of the constructs will
provide protection against diverse strains of the LD spirochetes and the causative agent of HGA. The resulting vaccine
will offer a new preventive strategy for these significant public health threats. The proposed work is timely, highly
significant and addresses an NIH priority area. This study will have broad overall impact as the knowledge gained can be
applied in the design of other epitope based multi-valent, multi-disease vaccines.
莱姆病(LD)和人类粒细胞无形体病(HGA)是严重威胁公共卫生的疾病。LD由以下原因引起
伯氏疏螺旋体、加里氏疏螺旋体、巴伐利亚疏螺旋体、阿氏疏螺旋体和HGA由无浆体吞噬细胞性肺炎(AP)引起。美国疾病控制与预防中心
据估计,美国每年约有33万名临床医生诊断为LD病例,其中欧洲和加拿大的数字较高。
自从2009年HGA被指定为可报告疾病以来,病例数量一直在稳步增加。2017年,4151起案件
美国报告的HGA数量(这个数字被认为被严重低估了)。当前的预防策略
对硬虱传播的疾病的治疗是不充分和无效的。随着LD和HGA流行区的扩大,
更好地认识它们的真实发病率、这些疾病的严重性以及相关的潜在并发症
如果是混合感染,就需要一种疫苗来预防多种壁虱传播的病原体。在这项研究中,我们将开发
嵌合的、基于线性表位的LD和HGA疫苗抗原(嵌合表位)。嵌合体的原理证明
一种高效的犬LD疫苗的成功开发证明了疫苗的有效性。最基本的
将应用于开发犬类疫苗的策略来构建两种LD的人类疫苗
和HGA。嵌合疫苗原将由LD的OspA、B和C蛋白的确定的线性表位组成
螺旋体和AP蛋白OmpA、Asp14和AipA的结构域。结构的多价性将
对不同的LD螺旋体菌株和HGA的病原体提供保护。由此产生的疫苗
将为这些重大公共卫生威胁提供一种新的预防战略。拟议的工作是及时的、高度的
具有重要意义,并涉及美国国立卫生研究院的优先领域。这项研究将产生广泛的整体影响,因为所获得的知识可以
应用于其他基于表位的多价、多病疫苗的设计。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
RICHARD T MARCONI其他文献
RICHARD T MARCONI的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('RICHARD T MARCONI', 18)}}的其他基金
OspC and its role in defining host range and dissemination properties
OspC 及其在定义主机范围和传播属性中的作用
- 批准号:
10345736 - 财政年份:2022
- 资助金额:
$ 64.37万 - 项目类别:
OspC and its role in defining host range and dissemination properties
OspC 及其在定义主机范围和传播属性中的作用
- 批准号:
10674690 - 财政年份:2022
- 资助金额:
$ 64.37万 - 项目类别:
Chimeric epitope based vaccines for tick borne infections
用于蜱传感染的嵌合表位疫苗
- 批准号:
10219068 - 财政年份:2019
- 资助金额:
$ 64.37万 - 项目类别:
Chimeric epitope based vaccines for tick borne infections
用于蜱传感染的嵌合表位疫苗
- 批准号:
10438610 - 财政年份:2019
- 资助金额:
$ 64.37万 - 项目类别:
Development of a multi-pathogen chimeritope vaccine for tick borne diseases
开发用于蜱传疾病的多病原体嵌合体疫苗
- 批准号:
9526584 - 财政年份:2017
- 资助金额:
$ 64.37万 - 项目类别:
Treponema denticola, complement regulatory proteins and periodontal disease
齿垢密螺旋体、补体调节蛋白和牙周病
- 批准号:
7208842 - 财政年份:2007
- 资助金额:
$ 64.37万 - 项目类别:
Treponema denticola, complement regulatory proteins and periodontal disease
齿垢密螺旋体、补体调节蛋白和牙周病
- 批准号:
8061662 - 财政年份:2007
- 资助金额:
$ 64.37万 - 项目类别:
Treponema denticola, complement regulatory proteins and periodontal disease
齿垢密螺旋体、补体调节蛋白和牙周病
- 批准号:
7807090 - 财政年份:2007
- 资助金额:
$ 64.37万 - 项目类别:
相似海外基金
Tick Immune Signaling, Microbiota, and Acquisition of Borrelia burgdorferi and Anaplasma phagocytophilum
蜱免疫信号传导、微生物群以及伯氏疏螺旋体和嗜吞噬细胞无形体的获得
- 批准号:
10222514 - 财政年份:2018
- 资助金额:
$ 64.37万 - 项目类别:
Tick Immune Signaling, Microbiota, and Acquisition of Borrelia burgdorferi and Anaplasma phagocytophilum
蜱免疫信号传导、微生物群以及伯氏疏螺旋体和嗜吞噬细胞无形体的获得
- 批准号:
9976322 - 财政年份:2018
- 资助金额:
$ 64.37万 - 项目类别:
Tick Immune Signaling, Microbiota, and Acquisition of Borrelia burgdorferi and Anaplasma phagocytophilum
蜱免疫信号传导、微生物群以及伯氏疏螺旋体和嗜吞噬细胞无形体的获得
- 批准号:
10440404 - 财政年份:2018
- 资助金额:
$ 64.37万 - 项目类别:
Anaplasma phagocytophilum modulate tick gene expression for its survival and transmission from the vector host
嗜吞噬细胞无形体调节蜱基因表达以使其存活并从载体宿主传播
- 批准号:
10322351 - 财政年份:2017
- 资助金额:
$ 64.37万 - 项目类别:
Anaplasma phagocytophilum modulate tick gene expression for its survival and transmission from the vector host
嗜吞噬细胞无形体调节蜱基因表达以使其存活并从载体宿主传播
- 批准号:
10203774 - 财政年份:2017
- 资助金额:
$ 64.37万 - 项目类别:
Anaplasma phagocytophilum modulate tick gene expression for its survival and transmission from the vector host
嗜吞噬细胞无形体调节蜱基因表达以使其存活并从载体宿主传播
- 批准号:
9398343 - 财政年份:2017
- 资助金额:
$ 64.37万 - 项目类别:
Dynamics of Anaplasma phagocytophilum infection through tick development
蜱发育过程中嗜吞噬细胞无形体感染的动态
- 批准号:
8868727 - 财政年份:2015
- 资助金额:
$ 64.37万 - 项目类别:
Anaplasma phagocytophilum hijacking of host cell monoubiquitination
嗜吞噬细胞无形体劫持宿主细胞单泛素化
- 批准号:
8637532 - 财政年份:2013
- 资助金额:
$ 64.37万 - 项目类别:
Anaplasma phagocytophilum hijacking of host cell monoubiquitination
嗜吞噬细胞无形体劫持宿主细胞单泛素化
- 批准号:
8784189 - 财政年份:2013
- 资助金额:
$ 64.37万 - 项目类别:
The roles of Anaplasma phagocytophilum surface proteins in cellular invasion
嗜吞噬细胞无形体表面蛋白在细胞侵袭中的作用
- 批准号:
8510769 - 财政年份:2012
- 资助金额:
$ 64.37万 - 项目类别: